✦ LIBER ✦

POTENCY AND SELECTIVITY OF THE NON-STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS

✍ Scribed by M. DOWSETT; R. C. STEIN; A. MEHTA; R. C. COOMBES

Book ID: 114719150
Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 788 KB
Volume: 32
Category: Article
ISSN: 0300-0664
DOI: 10.1111/j.1365-2265.1990.tb00906.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In vitro potency and selectivity of the

In vitro potency and selectivity of the non-steroidal androgen aromatase inhibitor CGS 16949A compared to steroidal inhibitors in the brain

✍ Wozniak, A.; Holman, S.D.; Hutchison, J.B. 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 602 KB

Effect of the potent aromatase inhibitor

Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma

✍ Luis A. M. Costa; Michael S. Kopreski; Laurence M. Demers; Vernon M. Chinchilli; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 1 views

## Background: Fadrozole hydrochloride (cgs 16949a) is a highly potent, nonsteroidal aromatase inhibitor that significantly lowers estrogen levels in postmenopausal women and can be effective therapy for patients with advanced hormone-dependent breast carcinoma. circulating estradiol, estrone, and

Effects of Fadrozole (CGS 16949A) and Le

Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

✍ Laurence M. Demers 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 672 KB

Phase II study of the eortc breast group

Phase II study of the eortc breast group with vorozole (R 83842), a new non-steroidal aromatase inhibitor in metastatic breast cancer (MBC) — preliminary results

✍ Paridaens, R.; Piccart, M.; Nooy, M.; Klijn, J.G.M.; Rubens, R.D.; Beex, L.; Tom 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 152 KB

A phase II study of a potent and selecti

A phase II study of a potent and selective aromatase inhibitor, anastrozole (ZD-1033), in Japanese postmenopausal women with advanced/recurrent breast cancer

✍ H. Koyama 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 147 KB

Pharmacokinetics and pharmacodynamics of

Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer

✍ Benjamin P. Haynes; Michael Jarman; Mitchell Dowsett; Anshumala Mehta; Per E. Lø 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 693 KB